Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Multiple Cancer Types

This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as pemetrexed and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving first-line pembrolizumab followed by pemetrexed and carboplatin with or without pembrolizumab works better in treating patients with non-squamous non-small cell cancer.
Lung, Non Small Cell
III
York, Sally
NCT03793179
ECOGTHOEA5163

9-ING-41 in Patients With Advanced Cancers

Multiple Cancer Types

GSK-3? is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1 / 2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3? inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
Miscellaneous, Phase I
I/II
Davis, Elizabeth
NCT03678883
VICCPHI19127

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Multiple Cancer Types

The main purpose of this study is to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.
Lung, Non Small Cell
II
Osmundson, Evan
NCT03840902
VICCTHO1917

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: